GlobeNewswire Inc.··NaWerewolf Therapeutics Explores Strategic Alternatives as Cash Runway Extends to Late 2026
Werewolf Therapeutics seeks strategic alternatives including potential sale or merger. Company reports improved 2025 financials, reduced losses, and $57.1M cash reserves.
HOWLfinancial resultsbiopharmaceutical